Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
Ardelyx (ARDX) Stock Looks Cheap Relative To Its Sales Base
Ardelyx (ARDX) Results And IBSRELA Progress Put Its Valuation Story Back In Focus
Ardelyx: 3 Key Takeaways for Long-Term Investors
Ardelyx (ARDX) Q3 2026 Earnings Call Transcript
Ardelyx, Inc. Q3 2026 Earnings Call Summary
Ardelyx: Upgrading To Hold After Q3, But Risks Still Dominate
Ardelyx Inc (ARDX) (Q3 2026) Earnings Call Highlights: Revenue Climbs 19% as IBSRELA Shines and ...
What Ardelyx (ARDX) Said on Its Q3 Earnings Call
Ardelyx (NASDAQ:ARDX) Q3 2026: Breakeven EPS, Revenue Miss, Guidance Held
Ardelyx, Inc. (ARDX) Q3 2026 Earnings Call Transcript
Ardelyx, Inc. 2026 Q3 - Results - Earnings Call Presentation
Ardelyx (ARDX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Ardelyx: Q3 Earnings Snapshot
Ardelyx (ARDX) Reports Break-Even Earnings for Q3
Ardelyx Reports Third Quarter 2026 Financial Results and Provides Business Update
Ardelyx Q3 2026 Earnings Call Transcript
Ardelyx Q3 Sales $125.500M Miss $128.420M Estimate
Ardelyx Completes Enrollment in Phase 3 ACCEL Clinical Trial of IBSRELA® (tenapanor) in Adults with Chronic Idiopathic Constipation
Ardelyx Completes Enrollment In Phase 3 ACCEL Clinical Trial Of IBSRELA
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.